ACT-709478

DRUG2 trials

Sponsors

Idorsia Pharmaceuticals Ltd.

Conditions

Healthy Subjects

Phase 1

Study to Evaluate Safety and Tolerability of ACT-709478 in Healthy Subjects

CompletedNCT03165097

Idorsia Pharmaceuticals Ltd.Healthy Subjects

Start: 2017-07-07End: 2018-12-28Updated: 2019-12-24

A Study to Compare a Single-dose of Two Different Formulations of ACT-709478 in Healthy Men

CompletedNCT04123288

Idorsia Pharmaceuticals Ltd.Healthy Subjects

Start: 2019-12-16End: 2020-02-05Updated: 2020-02-25

Related Papers

Multiple-Ascending Dose Study in Healthy Subjects to Assess the Pharmacokinetics, Tolerability, and CYP3A4 Interaction Potential of the T-Type Calcium Channel Blocker ACT-709478, A Potential New Antiepileptic Drug.

2020-03-017 citations